WASHINGTON (dpa-AFX) - Arena Pharmaceuticals, Inc. (ARNA), developer of the weight management drug Belviq, Tuesday said its pulmonary arterial hypertension drug, APD811, was granted orphan drug status by the US Food and Drug Administration.
'We are pleased with the OOPD's designation of orphan drug status for the active moiety of APD811, and we look forward to advancing this drug candidate into a Phase 2 clinical trial program later this year,' said Craig Audet, Senior VP of Arena.
Copyright RTT News/dpa-AFX